Baillie Gifford & Co. Sells 49,668 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Baillie Gifford & Co. lowered its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 69.9% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,403 shares of the biotechnology company’s stock after selling 49,668 shares during the quarter. Baillie Gifford & Co.’s holdings in Ascendis Pharma A/S were worth $3,196,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in ASND. Price T Rowe Associates Inc. MD raised its position in shares of Ascendis Pharma A/S by 23.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after purchasing an additional 336,976 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in Ascendis Pharma A/S by 63.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,142 shares of the biotechnology company’s stock valued at $1,664,000 after buying an additional 4,338 shares during the last quarter. Evolutionary Tree Capital Management LLC raised its holdings in Ascendis Pharma A/S by 82.3% in the 2nd quarter. Evolutionary Tree Capital Management LLC now owns 24,862 shares of the biotechnology company’s stock worth $3,391,000 after acquiring an additional 11,223 shares during the period. SG Americas Securities LLC lifted its position in Ascendis Pharma A/S by 221.0% during the 2nd quarter. SG Americas Securities LLC now owns 6,108 shares of the biotechnology company’s stock worth $833,000 after acquiring an additional 4,205 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its holdings in Ascendis Pharma A/S by 1,461.1% during the first quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock valued at $37,849,000 after acquiring an additional 234,446 shares during the period.

Ascendis Pharma A/S Stock Down 1.3 %

NASDAQ ASND opened at $126.03 on Thursday. Ascendis Pharma A/S has a twelve month low of $90.13 and a twelve month high of $161.00. The stock has a market cap of $7.64 billion, a P/E ratio of -13.54 and a beta of 0.66. The company’s 50-day simple moving average is $132.04 and its 200 day simple moving average is $132.86.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to the consensus estimate of $94.74 million. Research analysts anticipate that Ascendis Pharma A/S will post -7.35 earnings per share for the current year.

Analysts Set New Price Targets

ASND has been the topic of a number of recent analyst reports. Bank of America lifted their price objective on Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $170.00 price target on shares of Ascendis Pharma A/S in a research report on Monday, November 4th. Jefferies Financial Group increased their price objective on Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a research report on Tuesday, August 13th. Oppenheimer reiterated an “outperform” rating and set a $190.00 target price (up from $180.00) on shares of Ascendis Pharma A/S in a research note on Tuesday, September 17th. Finally, Wells Fargo & Company raised their price target on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 17th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Ascendis Pharma A/S currently has an average rating of “Moderate Buy” and a consensus price target of $195.92.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.